Insight Molecular Diagnostics Inc. (IMDX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 3M 6M 9M Q4 '20: 1.2M Q1 '21: 2.3M Q2 '21: 4.2M Q3 '21: 4.6M Q4 '21: 7.7M Q1 '22: 7M Q2 '22: 5.2M Q3 '22: 4.3M Q4 '22: 958K Q1 '23: 875K Q2 '23: 1.1M Q3 '23: 1.5M Q4 '23: 1.5M Q1 '24: 1.4M Q2 '24: 1M Q3 '24: 709K Q4 '24: 1.9M Q1 '25: 3.8M Q2 '25: 4.3M Q3 '25: 4.4M Q4 '25: 4.1M Q1 '26: 1.9M Q2 '26: 1.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

-1.8M -900K 0 900K 1.8M 2.7M Q4 '20: -639K Q1 '21: -402K Q2 '21: -574K Q3 '21: -1.4M Q4 '21: 1.4M Q1 '22: 1.6M Q2 '22: 2M Q3 '22: 2.6M Q4 '22: -18K Q1 '23: -255K Q2 '23: -14K Q3 '23: 503K Q4 '24: 740K Q1 '25: 2M Q2 '25: 2.3M Q3 '25: 2.4M Q4 '25: 2.3M Q1 '26: 988K Q2 '26: 807K Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -11.6M Q4 '16: -11.1M Q1 '17: -12.7M Q2 '17: -13.8M Q3 '17: -18.1M Q4 '17: -18.8M Q1 '18: -18.2M Q2 '18: -18.9M Q3 '18: -15M Q4 '18: -15.2M Q1 '19: -15.3M Q2 '19: -16.5M Q3 '19: -18.8M Q4 '19: -22.2M Q1 '20: -26.7M Q2 '20: -30M Q3 '20: -31M Q4 '20: -29.7M Q1 '21: -32.6M Q2 '21: -37.4M Q3 '21: -44.8M Q4 '21: -74.2M Q1 '22: -65.9M Q2 '22: -53.9M Q3 '22: -42M Q4 '22: -18M Q1 '23: -9.1M Q2 '23: -15.8M Q3 '23: -20.6M Q4 '23: -25.1M Q1 '24: -40.3M Q2 '24: -36.6M Q3 '24: -43.6M Q4 '24: -61M Q1 '25: -58.6M Q2 '25: -63.8M Q3 '25: -61.3M Q4 '25: -51.1M Q1 '26: -48.7M Q2 '26: -50.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q3 '16: -11.6M Q4 '16: -11.2M Q1 '17: -12.9M Q2 '17: -14.2M Q3 '17: -18.5M Q4 '17: -19.4M Q1 '18: -18.4M Q2 '18: -19.1M Q3 '18: -15.2M Q4 '18: -15.8M Q1 '19: -15.8M Q2 '19: -16.7M Q3 '19: -19M Q4 '19: -22.4M Q1 '20: -26.3M Q2 '20: -30M Q3 '20: -31.6M Q4 '20: -29.9M Q1 '21: -26.1M Q2 '21: -27.5M Q3 '21: -34.5M Q4 '21: -64.1M Q1 '22: -70.5M Q2 '22: -68.3M Q3 '22: -63.8M Q4 '22: -72.9M Q1 '23: -59.6M Q2 '23: -59.6M Q3 '23: -56.8M Q4 '23: -27.8M Q1 '24: -39.9M Q2 '24: -36.1M Q3 '24: -43.1M Q4 '24: -60.7M Q1 '25: -58.2M Q2 '25: -63.4M Q3 '25: -60.8M Q4 '25: -50.2M Q1 '26: -47.8M Q2 '26: -49.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 2M 4M 6M Q4 '20: 1.8M Q1 '21: 2.4M Q2 '21: 3.4M Q3 '21: 3.7M Q4 '21: 5.2M Q1 '22: 4.5M Q2 '22: 3.4M Q3 '22: 2.8M Q4 '22: 880K Q1 '23: 1M Q2 '23: 1M Q3 '23: 871K Q4 '23: 1M Q1 '24: 846K Q2 '24: 709K Q3 '24: 593K Q4 '24: 1.1M Q1 '25: 1.8M Q2 '25: 1.9M Q3 '25: 2M Q4 '25: 1.8M Q1 '26: 961K Q2 '26: 863K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '16: -6.7M Q4 '16: -7.5M Q1 '17: -8.6M Q2 '17: -10.1M Q3 '17: -12.6M Q4 '17: -13.4M Q1 '18: -12.8M Q2 '18: -13.5M Q3 '18: -12.5M Q4 '18: -11.6M Q1 '19: -15.6M Q2 '19: -14.5M Q3 '19: -16.9M Q4 '19: -19.7M Q1 '20: -19.9M Q2 '20: -24M Q3 '20: -25.1M Q4 '20: -26M Q1 '21: -28.9M Q2 '21: -30M Q3 '21: -35M Q4 '21: -35.9M Q1 '22: -39.4M Q2 '22: -42.6M Q3 '22: -43M Q4 '22: -45.6M Q1 '23: -40.6M Q2 '23: -36.2M Q3 '23: -28.5M Q4 '23: -23.3M Q1 '24: -18.9M Q2 '24: -18M Q3 '24: -19.8M Q4 '24: -20.7M Q1 '25: -22.7M Q2 '25: -22.9M Q3 '25: -22M Q4 '25: -22.2M Q1 '26: -24M Q2 '26: -27.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q4 '15: -4.7M Q1 '16: -6.7M Q2 '16: -7.6M Q3 '16: -7.2M Q4 '16: -7.6M Q1 '17: -8.8M Q2 '17: -10.3M Q3 '17: -12.7M Q4 '17: -13.5M Q1 '18: -12.9M Q2 '18: -13.6M Q3 '18: -12.6M Q4 '18: -11.7M Q1 '19: -15.6M Q2 '19: -14.5M Q3 '19: -16.9M Q4 '19: -20.6M Q1 '20: -20.8M Q2 '20: -25.4M Q3 '20: -27.1M Q4 '20: -27.2M Q1 '21: -31M Q2 '21: -32.2M Q3 '21: -37M Q4 '21: -38.2M Q1 '22: -42.3M Q2 '22: -46M Q3 '22: -46.9M Q4 '22: -49.9M Q3 '24: -20.3M Q4 '24: -21.2M Q1 '25: -23.5M Q2 '25: -23.9M Q3 '25: -23.9M Q4 '25: -25.4M Q1 '26: -27.5M Q2 '26: -31M Q1 '16 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '21: 82.1M Q2 '21: 89.8M Q3 '21: 91.5M Q1 '22: 92.2M Q2 '22: 5.7K Q3 '22: 5.9K Q1 '23: 6M Q2 '23: 8.1M Q3 '23: 8.3M Q1 '24: 8.3M Q2 '24: 12.9M Q3 '24: 13.7M Q1 '25: 25.7M Q2 '25: 32M Q3 '25: 32M Q1 '26: 34.5M Q2 '26: 36.8M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '15: -0.43 Q1 '16: -0.47 Q2 '16: -0.50 Q3 '16: -0.48 Q4 '16: -0.43 Q1 '17: -0.47 Q2 '17: -0.50 Q3 '17: -0.62 Q4 '17: -0.63 Q1 '18: -0.59 Q2 '18: -0.58 Q3 '18: -0.43 Q4 '18: -0.43 Q1 '19: -0.39 Q2 '19: -0.37 Q3 '19: -0.40 Q4 '19: -0.43 Q1 '20: -0.48 Q2 '20: -0.24 Q3 '20: -0.24 Q4 '20: -0.19 Q1 '21: -0.11 Q2 '21: -0.13 Q3 '21: -0.18 Q4 '21: -0.48 Q1 '22: -0.54 Q3 '23: -9.51 Q4 '23: -3.55 Q1 '24: -5.08 Q2 '24: -4.37 Q3 '24: -4.54 Q4 '24: -4.77 Q1 '25: -3.90 Q2 '25: -3.84 Q3 '25: -3.20 Q4 '25: -1.64 Q1 '26: -1.50 Q2 '26: -1.51 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.